Home > Newsletters > Drug Industry Daily > FDA Reviewers Focus on Liver Risks of Genzyme HoFH Drug, Analyst Expects Approval
Drug Industry Daily
Oct. 17, 2012 | Vol. 11 No. 204
FDA Reviewers Focus on Liver Risks of Genzyme HoFH Drug, Analyst Expects Approval
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Thursday will discuss a number of liver-related and carcinogenic adverse events seen in four Phase III trials of Genzyme and Isis Pharmaceuticals’ Kynamro as a treatment for homozygous familial hypercholesterolemia (HoFH), a life-threatening genetic disorder.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.